First, I apologize as that comment was not directed at you, but rather in response to another poster who talks about it more then almost anything else. I agree that if we are diluting to cover mistakes from the past and over pay personnel then it is counter productive. If on the other hand it is a choice of diluting in order to develop our main product and to put it through all the regulatory hoops so we can get it to market, or close the doors because we don't have the funds to carry it out then I chose dilution. My thinking is a smaller chunk of something is better then a lot of nothing.
Having said all of that, I have come to the conclusion that we have far over spent in the past in very unwise ways (like paying Jonnie & Paul 1 million dollars each per year as the company bled red and untold millions spent in a court battle that seems to have been in vane with no prospects for anymore income from it on the horizon). The result is we have had to increase share count just to keep going. I am a believer that our new management will get focused on the things that matter and will stay focused on that. The hurdles ahead will be successfully navigating the FDA trials instead of the courts (let's hope anyways).
Again, I do apologize for any inferences that I was responding to you with my previous comments.
News 
Market Data 
Discover 
